Immunopeptidomics identified antigens for mRNA-lipid nanoparticle vaccines with alpha-galactosylceramide in multiple myeloma therapy.
Saved in:
| Title: | Immunopeptidomics identified antigens for mRNA-lipid nanoparticle vaccines with alpha-galactosylceramide in multiple myeloma therapy. |
|---|---|
| Authors: | Van der Vreken A; Department of Biomedical Sciences Brussels, Translational Oncology Research Center, Vrije Universiteit Brussel, Brussels, Belgium karine.breckpot@vub.be Eline.Menu@vub.be arne.van.der.vreken@vub.be., Thery F; VIB-UGent Center for Medical Biotechnology, VIB, Ghent, Belgium.; Department of Biomolecular Medicine, Ghent University, Ghent, Belgium., Tu C; Department of Biomedical Sciences Brussels, Translational Oncology Research Center, Vrije Universiteit Brussel, Brussels, Belgium., Mwangi K; Department of Pharmaceutics, Laboratory of Physical Pharmacy and General Biochemistry, Ghent Research Group on Nanomedicines, Universiteit Gent, Ghent, Belgium.; Cancer Research Institute Ghent (CRIG), Universiteit Gent, Ghent, Belgium., Meulewaeter S; Department of Pharmaceutics, Laboratory of Physical Pharmacy and General Biochemistry, Ghent Research Group on Nanomedicines, Universiteit Gent, Ghent, Belgium.; Cancer Research Institute Ghent (CRIG), Universiteit Gent, Ghent, Belgium., De Beck L; Department of Biomedical Sciences Brussels, Translational Oncology Research Center, Vrije Universiteit Brussel, Brussels, Belgium., Janssens E; Department of Biomedical Sciences Brussels, Translational Oncology Research Center, Vrije Universiteit Brussel, Brussels, Belgium., De Veirman K; Department of Biomedical Sciences Brussels, Translational Oncology Research Center, Vrije Universiteit Brussel, Brussels, Belgium., Vanderkerken K; Department of Biomedical Sciences Brussels, Translational Oncology Research Center, Vrije Universiteit Brussel, Brussels, Belgium., De Bruyne E; Department of Biomedical Sciences Brussels, Translational Oncology Research Center, Vrije Universiteit Brussel, Brussels, Belgium., Franceschini L; Department of Biomedical Sciences Brussels, Translational Oncology Research Center, Vrije Universiteit Brussel, Brussels, Belgium., Impens F; VIB-UGent Center for Medical Biotechnology, VIB, Ghent, Belgium.; Department of Biomolecular Medicine, Ghent University, Ghent, Belgium., Verbeke R; Department of Pharmaceutics, Laboratory of Physical Pharmacy and General Biochemistry, Ghent Research Group on Nanomedicines, Universiteit Gent, Ghent, Belgium.; Cancer Research Institute Ghent (CRIG), Universiteit Gent, Ghent, Belgium., Lentacker I; Department of Pharmaceutics, Laboratory of Physical Pharmacy and General Biochemistry, Ghent Research Group on Nanomedicines, Universiteit Gent, Ghent, Belgium.; Cancer Research Institute Ghent (CRIG), Universiteit Gent, Ghent, Belgium., Menu E; Department of Biomedical Sciences Brussels, Translational Oncology Research Center, Vrije Universiteit Brussel, Brussels, Belgium karine.breckpot@vub.be Eline.Menu@vub.be arne.van.der.vreken@vub.be., Breckpot K; Department of Biomedical Sciences Brussels, Translational Oncology Research Center, Vrije Universiteit Brussel, Brussels, Belgium karine.breckpot@vub.be Eline.Menu@vub.be arne.van.der.vreken@vub.be. |
| Source: | Journal for immunotherapy of cancer [J Immunother Cancer] 2025 Apr 29; Vol. 13 (4). Date of Electronic Publication: 2025 Apr 29. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Electronic Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
